Search details
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Article
in English
| MEDLINE | ID: mdl-37256976
2.
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
Lancet Oncol
; 25(4): e139-e151, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38547898
3.
Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
Breast Cancer Res Treat
; 195(3): 333-340, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35976513
4.
Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience.
Breast Cancer Res Treat
; 192(3): 563-571, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-35119530
5.
Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience.
Br J Cancer
; 125(2): 299-304, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34017085
6.
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
Lancet
; 395(10226): 817-827, 2020 03 07.
Article
in English
| MEDLINE | ID: mdl-32145796
7.
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Oncologist
; 26(8): e1339-e1346, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34037282
8.
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
Oncologist
; 26(7): e1143-e1155, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33955129
9.
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Oncologist
; 26(5): e749-e755, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33486783
10.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 379(20): 1926-1936, 2018 Nov 15.
Article
in English
| MEDLINE | ID: mdl-30345905
11.
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Lancet Oncol
; 21(10): 1296-1308, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32919527
12.
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Breast Cancer Res Treat
; 184(1): 23-35, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-32783178
13.
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.
Clin Chem
; 65(11): 1405-1413, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31551314
14.
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.
Lancet
; 389(10087): 2403-2414, 2017 Jun 17.
Article
in English
| MEDLINE | ID: mdl-27939057
15.
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 373(3): 209-19, 2015 Jul 16.
Article
in English
| MEDLINE | ID: mdl-26030518
16.
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Oncologist
; 22(9): 1028-1038, 2017 09.
Article
in English
| MEDLINE | ID: mdl-28652278
17.
Palbociclib and Fulvestrant in Breast Cancer. Reply.
N Engl J Med
; 380(8): 797, 2019 Feb 21.
Article
in English
| MEDLINE | ID: mdl-30786200
18.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Lancet Oncol
; 17(4): 425-439, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26947331
19.
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Oncologist
; 21(10): 1165-1175, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27368881
20.
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Cancer Cell
; 13(2): 91-104, 2008 Feb.
Article
in English
| MEDLINE | ID: mdl-18242510